Prolynx Data Points to Quarterly Obesity Dosing in Rats

Every result in this story comes from rats. Prolynx, an Emeryville, California, biotechnology company, presented preclinical data at ObesityWeek 2026 on Saturday, November 14, 2026, in three poster presentations. The headline result: a single dose of an amylin agonist sustained weight loss for 12 weeks in rats with diet-induced obesity. A second candidate, a GLP-1/GIP dual agonist, reached a half-life greater than one month. The company says the data support the potential for dosing anti-obesity peptides once a month to once a quarter.

The mechanism is the claim underneath the numbers. Most long-acting obesity peptides rely on fatty-acid lipidation, which binds the drug to albumin and generally limits practical half-life to about one week. Prolynx's platform works differently: peptides are covalently tethered to biodegradable hydrogel microspheres through releasable linkers that cleave at a preprogrammed rate. Half-life is set by the linker chemistry and by release from the depot, not by the peptide alone, and the company says that keeps peak concentrations low and peak-to-trough fluctuation small.

The three posters divide the argument into parts. Poster 101 reports the ultralong-acting amylin agonist and its sustained 12-week weight loss after a single dose. Poster 228 reports that unlipidated anti-obesity peptides achieved body weight reductions similar to those of their lipidated counterparts. Poster 236 presents the platform itself, as a route to ultralong-acting peptide therapeutics that doesn't depend on lipidation. All three were presented on November 14, from 7:30 to 8:30 p.m. ET, and are posted on the company's website.

“Today's obesity medicines have transformed care, but weekly injections and dosing-related side effects remain real barriers to long-term treatment,” said Chris Boulton, Prolynx's chief executive. He said the three presentations show the platform working across incretin and amylin biology, and that they strengthen the company's conviction that “once-monthly induction, once-quarterly maintenance therapies are within reach.” Amer Mirza, the chief scientific officer, said the platform uncouples a peptide's intrinsic potency from its exposure profile, so the team can choose the best peptide and then program how long it lasts.

The distance between this data and a medicine is the part to keep in view. These are nonclinical results in diet-induced obese rats, presented as conference posters by the company developing the platform. There's no human dosing, no human safety data and no regulatory filing in the announcement, and a half-life past one month in a rat doesn't schedule a quarterly injection in a person. What the posters establish is narrower: the linker approach extended exposure over several months in animals while preserving weight-loss efficacy comparable to lipidated peptides.

Prolynx is backed by 5AM Ventures, OrbiMed and Monograph Capital, and it's building a portfolio across incretin and non-incretin targets for obesity and related metabolic diseases. Its next proof point isn't another poster. It's whether the predictable pharmacokinetics it reports in animals survive the move into a first human study, which the announcement doesn't date.